on-invasive measurement of mitochondrial function in vivo (NIMFO) in septic patients

Completed

• Conditions: Sepsis, COVID-19; COVID-19; sepsis

• Registration Number: NL-OMON55883
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 45

Inclusion Criteria

Intensive care patients:
In order to be eligible to participate in this study, a subject must meet the
following criteria:

* 18-90 years of age
* Admission to intensive care ward within 72 hours before inclusion

Aged and gender matched healthy controls:
* 18-90 years of age
* No relevant comorbidities (ASA I/II)
* Matched in age (±5 years) and gender to one of the participants in the
COVID-19 group.

Exclusion Criteria

* Mentally disabled
* Porphyria
* Presence of mitochondrial disease

Healthy controls group:
* Presence of COVID-19/sepsis related complains or symptoms
* Presence of COVID-19/sepsis symptoms or complains, or a positive COVID-19
test less than one month ago
* COVID-19 vaccination less than two weeks ago

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>COMET;<br /><br>Mitochondrial function (ODR) </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Cellular oxygen availability in skin (mitoPO2 in mmHg)<br /><br>Mitochondrial function in platelets<br /><br>Mitochondrial DNA in plasma as a marker of mitochondrial damage<br /><br>Microvasculair bloodflow measured by O2C<br /><br>Capillary refill time sternum<br /><br>Mitochondrial function in peripheral blood mononuclear cells</p><br>